Expert Review of Precision Medicine and Drug Development

Expert Review of Precision Medicine and Drug Development 由 Taylor & Francis 出版，属中科院医学大类（2025 升级版4区）。按 OpenAlex 近年发文统计，该刊主要发表 Cancer Genomics and Diagnostics、Cancer Immunotherapy and Biomarkers、Lung Cancer Treatments and Mutations 等主题的论文，这 3 个主题约占 31.9%，主导子领域为 Oncology。（根据 OpenAlex 主题统计与中科院分区数据生成）

This journal has ceased (2025) *Please note that Expert Review of Precision Medicine and Drug Development converted to a full Open Access journal from Volume 8 (2023). Previous volumes will continue to provide access through a Pay to Read model. Expert Review of Precision Medicine and Drug Development [e-ISSN 2380-8993] is an international open access journal publishing rigorously peer-reviewed review articles and original papers on the development and clinical application of medicine to be used in a personalised therapy setting. In an era where medicine is recognizing that a one-size-fits-all approach is not always appropriate, Expert Review of Precision Medicine and Drug Development supports the necessity to identify patients responsive to treatments and treat patient populations using a tailored approach. Articles focus on the following key areas: Development and application of drugs targeted to specific genotypes and populations, as well as advanced diagnostic technologies and significant biomarkers that aid in this; Clinical trials within personalised therapy and drug development; Screening, prediction and prevention of disease, prediction of adverse events, treatment monitoring, effects of metabolomics and microbiomics on treatment; Secondary population research, genome-wide association studies, disease–gene association studies, personal genome technologies; Ethical and cost–benefit issues, the impact to healthcare and business infrastructure, and regulatory issues. Please note that the journal does not publish case reports, case series or animal studies Comprehensive coverage in each review is complemented by the unique Expert Collection format and includes the following sections: Expert Opinion – a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results; Article Highlights – an executive summary of the author’s most critical points. Once your paper has been assessed for suitability by the Editorial Team, it will then be double-anonymous peer-reviewed by independent, expert referees. Reach an international clinical and medical audience alongside other key opinion leaders in your field by publishing with Expert Review of Precision Medicine and Drug Development, part of the Expert Collection brand. For any pre-submission enquiries, please contact the Commissioning Editor. Sorry

摘自期刊官网 Aims & Scope

研究方向（LetPub）：PHARMACOLOGY & PHARMACY

主编 Liang Cheng出版商官网

编委会国家分布：未见中国大陆编委；主要国家 美国 7、意大利 3、中国香港 2、英国 2、西班牙 2（共 25 位编委标注了国家） 编委会 ↗出版商官网 · 2026-10-01

中科院期刊分区表

数据库收录

ESCIScopusLetPub

国际期刊预警名单：各版本均未列入LetPub

不同版本、大类与小类分别展示，不将不同评价口径合并为一个分区值；投稿与考核前请确认所在机构采用的版本。

影响力指标

CiteScore 2026-06

2.3LetPub · 2026-09-13

SJR 2026-06

0.25LetPub · 2026-09-13

SNIP 2026-06

0.33LetPub · 2026-09-13

h-index

22OpenAlex · 2026-10-01

i10-index

71OpenAlex · 2026-10-01

两年平均被引

3.6OpenAlex · 2026-10-01

自引率

0%LetPub · 2026-09-13

Gold OA 文章占比

20%LetPub · 2026-09-13

发文规模

年文章数

4LetPub · 2026-09-13

不同来源的统计口径与观测时间不同，页面保留各来源原值；“出版商公布”为期刊官网自述数据。

其他来源

评审方式

双盲同行评审出版商官网

社区反馈来自投稿者样本，置信度 0.5，不代表期刊承诺；“出版商公布”的时间节点定义以官网为准。

混合期刊的文章处理费仅在作者选择开放获取发表时收取；按订阅方式发表通常不收费。

费用以期刊官网为准；不同来源的观测时间可能不同，页面保留各来源原值，不做平均。

摘录来自期刊官网页面，仅保留原文片段；“模型摘要”由 Workers AI 生成并经原文校验，以官网为准。

出版商

Taylor & Francis

ISSN

2380-8993

官网最新一期

Volume 10, Issue 1（2025 年）

官方链接

• 期刊主页 ↗LetPub